What The Study Did:
This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab vs placebo on change in day 11 severe acute respiratory syndrome coronavirus 2 viral load in patients with mild to moderate COVID-19.
Authors:
Daniel M. Skovronsky, M.D., Ph.D., of Eli Lilly and Company in Indianapolis, is the corresponding author.
To access the embargoed study:
Visit our For The Media website at this link
https://media.jamanetwork.com/
(doi:10.1001/jama.2021.0202)
Editor's Note: The articles includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Media advisory:The full article is linked to this news release.
Embed this link to provide your readers free access to the full-text article
This link will be live at the embargo time
https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2021.0202?guestAccessKey=3fec263c-09fb-401a-b5b9-3691cf340d8b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=012121
Journal
JAMA